Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants

CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiskopf, Kipp, Ring, Aaron M, Schnorr, Peter J, Volkmer, Jens-Peter, Volkmer, Anne Kathrin, Weissman, Irving L, Garcia, K Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850276/
https://www.ncbi.nlm.nih.gov/pubmed/24319639
http://dx.doi.org/10.4161/onci.25773
_version_ 1782294067301842944
author Weiskopf, Kipp
Ring, Aaron M
Schnorr, Peter J
Volkmer, Jens-Peter
Volkmer, Anne Kathrin
Weissman, Irving L
Garcia, K Christopher
author_facet Weiskopf, Kipp
Ring, Aaron M
Schnorr, Peter J
Volkmer, Jens-Peter
Volkmer, Anne Kathrin
Weissman, Irving L
Garcia, K Christopher
author_sort Weiskopf, Kipp
collection PubMed
description CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeutics. These high-affinity SIRPα variants synergize with antineoplastic antibodies by lowering the threshold for macrophage-mediated destruction of malignant cells.
format Online
Article
Text
id pubmed-3850276
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38502762013-12-06 Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants Weiskopf, Kipp Ring, Aaron M Schnorr, Peter J Volkmer, Jens-Peter Volkmer, Anne Kathrin Weissman, Irving L Garcia, K Christopher Oncoimmunology Author's View CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeutics. These high-affinity SIRPα variants synergize with antineoplastic antibodies by lowering the threshold for macrophage-mediated destruction of malignant cells. Landes Bioscience 2013-09-01 2013-07-29 /pmc/articles/PMC3850276/ /pubmed/24319639 http://dx.doi.org/10.4161/onci.25773 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Weiskopf, Kipp
Ring, Aaron M
Schnorr, Peter J
Volkmer, Jens-Peter
Volkmer, Anne Kathrin
Weissman, Irving L
Garcia, K Christopher
Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title_full Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title_fullStr Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title_full_unstemmed Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title_short Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
title_sort improving macrophage responses to therapeutic antibodies by molecular engineering of sirpα variants
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850276/
https://www.ncbi.nlm.nih.gov/pubmed/24319639
http://dx.doi.org/10.4161/onci.25773
work_keys_str_mv AT weiskopfkipp improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT ringaaronm improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT schnorrpeterj improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT volkmerjenspeter improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT volkmerannekathrin improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT weissmanirvingl improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants
AT garciakchristopher improvingmacrophageresponsestotherapeuticantibodiesbymolecularengineeringofsirpavariants

Ejemplares similares